Journal article
Targeting protein prenylation in progeria
Science translational medicine, Vol.5(171), pp.171ps3-171ps3
02/06/2013
DOI: 10.1126/scitranslmed.3005229
PMCID: PMC3725554
PMID: 23390246
Abstract
A clinical trial of a protein farnesyltransferase inhibitor (lonafarnib) for the treatment of Hutchinson-Gilford progeria syndrome (HGPS) was recently completed. Here, we discuss the mutation that causes HGPS, the rationale for inhibiting protein farnesyltransferase, the potential limitations of this therapeutic approach, and new potential strategies for treating the disease.
Details
- Title: Subtitle
- Targeting protein prenylation in progeria
- Creators
- Stephen G Young - Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA. sgyoung@mednetShao H YangBrandon S J DaviesHea-Jin JungLoren G Fong
- Resource Type
- Journal article
- Publication Details
- Science translational medicine, Vol.5(171), pp.171ps3-171ps3
- DOI
- 10.1126/scitranslmed.3005229
- PMID
- 23390246
- PMCID
- PMC3725554
- NLM abbreviation
- Sci Transl Med
- ISSN
- 1946-6234
- eISSN
- 1946-6242
- Publisher
- United States
- Grant note
- AG035626 / NIA NIH HHS HL089781 / NHLBI NIH HHS R01 HL089781 / NHLBI NIH HHS R01 AG035626 / NIA NIH HHS R01 HL086683 / NHLBI NIH HHS HL086683 / NHLBI NIH HHS
- Language
- English
- Date published
- 02/06/2013
- Academic Unit
- Fraternal Order of Eagles Diabetes Research Center; Biochemistry and Molecular Biology
- Record Identifier
- 9984024542902771
Metrics
20 Record Views